ClavystBio

Thank you to all our partners and friends, especially those who travelled long distances, for joining us at ClavystBio Connects 2023. We look forward to furthering the great connections and rich conversations that day! For those who weren't able to join, here's a short video of the day's highlights. Enjoy! #collaboratetoinnovate #clavystbio #clavystbioconnects

We’re thrilled to welcome Anselm T. as he joins our leadership team to build our Digital Health and MedTech segment.  Anselm's extensive background and expertise in venture capital and health technology will be invaluable as we continue to drive meaningful innovations towards global health impact. Learn more about Anselm and the ClavystBio team here: https://lnkd.in/ghWAB_gb

ClavystBio CEO Khoo Shih recently shared her insights on the momentum in Singapore’s life sciences sector with The Straits Times’ Timothy Goh.  “Singapore’s #biomedical industry has a strong foundation, poised for sustainable growth” she said. “Global pharmaceutical companies and investors are attracted by the world-class #innovation, well-trained scientific talent, excellent clinical infrastructure and strong government support. We see tremendous potential in investing and growing biomedical companies from Singapore with global health impact.” Read the full article here [subscriber access]: https://lnkd.in/gFB3Mzqu

What does it take to successfully advance and navigate biotech deals? Join our upcoming ClavystBio Conversation and hear directly from seasoned biotech executives with hands-on experience and an impressive track record in investing, operating and overseeing biotech M&As and business partnerships. Co-organized with Enterprise Singapore, the panel will be followed by a networking session. Don't miss this opportunity to gain insights and connect with speakers Luc Dochez, George Golumbeski, Christina K. Isacson Ph.D., Andreas Wallnoefer, Khoo Shih. and other industry players! Registration closes Fri, 1 Nov. Sign up here: https://lnkd.in/grjf4cnp ClavystBio Enterprise Singapore Droia Ventures Lightstone Ventures #clavystbioconversations #clavystcommunity

Our portfolio company Sunbird Bio bolsters the clinical development of its blood-based diagnostic platform with additional funding from new investors Eli Lilly and Company and EDBI Pte Ltd, alongside existing investors ClavystBio, Polaris Partners and S32.

Catch ClavystBio CEO Khoo Shih and our portfolio company Engine Biosciences CEO Jeffrey Lu in CNA's latest documentary, highlighting the transformative impact of biotech innovation!

🎥 Step into ClavystBio Node 1….We had a blast capturing the energy of our awesome community and space at Singapore Science Park. A hub for innovators, Node 1 offers labs and offices for life sciences ventures that have graduated from incubators to progress to their next milestones. Discover more here: https://lnkd.in/gDRPqsGn Automera CoV Biotechnology Paratus Sciences ClavystBio Polaris Partners 4BIO Capital Nanodigmbio Biotechnology #65LAB #clavystcommunity #collaboratetoinnovate

Thrilled to share this exciting collaboration between National Heart Centre Singapore and Paratus Sciences. Together, we are paving the way for breakthroughs in #cardiovascular research and #drug #discovery. https://lnkd.in/e-JQ936q #batbiology #therapeutics #innovation #inflammation #cardiometabolism Derek Hausenloy Polaris Partners ARCH Venture Partners ClavystBio Leaps by Bayer EcoR1 Capital, LLC Alexandria Center for Life Science

MediSix Therapeutics Founder Prof Dario Campana’s latest research, published in Nature Medicine, sheds new light on treating T-cell Acute Lymphoblastic Leukemia (T-ALL). It highlights the promise of CAR T cell therapy for patients struggling with relapsed or chemo-resistant T-ALL. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 𝗜𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆:  16 out of 17 patients achieved complete remission with minimal residual disease within just one month. 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 CAR T cell therapy demonstrated strong anti-leukemic activity with mild toxicity. 𝗜𝗺𝗺𝘂𝗻𝗲 𝘀𝘆𝘀𝘁𝗲𝗺 𝗿𝗲𝗰𝗼𝘃𝗲𝗿𝘆: Despite powerful anti-leukemic activity, the treatment allowed for the regeneration of polyclonal and functional T cells. These results underscore the potential of MediSix's innovative CAR T cell therapies, and offer new hope to T-ALL patients who have exhausted conventional treatment options. Learn more here: https://lnkd.in/e2h8Wg2H Nature Portfolio MediSix Therapeutics National University Health System #cancerresearch #clavystcommunity

🎉 Applications Now Open: Nucleate Ignite VC Workshop 2024/25 🚀 After the success of last year’s Ignite VC Workshop, we’re thrilled to bring it back for 2024-2025! Join us for the first workshop of the new term as we deliver exclusive insights into the venture capital journey within the life sciences industry. Whether you're a student, aspiring entrepreneur, or industry professional, this is your chance to learn from experienced industry leaders through in-person sessions designed to equip you with the skills to thrive in biotech VC. Workshop Sessions: 📅 Dr. Ho Wen Qi Introduction to Life Science Venture Capital Date: 23rd Oct, Wed, 6-8pm Affiliation: Therapeutics Lead, ClavystBio 📅 Dr. Alice Chen Due Diligence of Life Science Companies Date: 29th Oct, Tues, 6-8pm Affiliation: Executive Vice President, Accelerator Life Science Partners 📅 Dr. Kim Png Introduction to Startup Valuation and Other Deal Considerations Date: 5th Nov, Tues, 6-8pm Affiliation: Principal, Polaris Partners 📍 Venue: To be disclosed to confirmed participants RSVP here: https://lnkd.in/gUCQhQSN Don’t miss out on this invaluable learning experience—spots are limited, so secure yours today and kickstart your VC journey! 💡 Nucleate SG P&E Team: Shruti Sridhar, Gloria Chan, Roshni Gupta, Jashan Singh, Panida C. Nucleate SG: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, Jiaqi Liang, Ivan Seah, MBBS/MBA/MPH, John Joson Ng, Damien Chua, Isha Karnik, Senuri De Silva, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Devika Menon #VentureCapital #LifeSciences #Entrepreneurship #NucleateIgnite #BiotechNetworking #Leadership